Neuromuscular disorders: molecular and therapeutic insights.
Mastaglia
Frank L
FL
Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Queen Elizabeth II Medical Centre, Perth, Western Australia, Australia. flmast@cyllene.uwa.edu.au
D016123:Campylobacter jejuni / Q000302:isolation & purification; D049310:Distal Myopathies / Q000188:drug therapy / Q000378:metabolism; D004359:Drug Therapy, Combination; D005677:G(M1) Ganglioside / Q000378:metabolism; D020275:Guillain-Barre Syndrome / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D015803:HLA-DR3 Antigen / Q000235:genetics; D006239:Haplotypes; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008070:Lipopolysaccharides / Q000378:metabolism; D008775:Methylprednisolone / Q000627:therapeutic use; D009154:Mutation; D018979:Myositis, Inclusion Body / Q000188:drug therapy / Q000378:metabolism; D009468:Neuromuscular Diseases / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000378:metabolism* / Q000382:microbiology; D016032:Randomized Controlled Trials as Topic
D015803:HLA-DR3 Antigen; D016756:Immunoglobulins, Intravenous; D008070:Lipopolysaccharides; D005677:G(M1) Ganglioside; D008775:Methylprednisolone